Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study. Issue 3 (21st December 2022)

• Record Type: Journal Article
• Authors: Fusaroli, Michele; Giunchi, Valentina; Battini, Vera; Gringeri, Michele; Rimondini, Roberto; Menchetti, Marco; Radice, Sonia; Pozzi, Marco; Nobile, Maria; Clementi, Emilio; De Ponti, Fabrizio; Carnovale, Carla; Raschi, Emanuel; Poluzzi, Elisabetta
• Is Part Of: Psychiatry and clinical neurosciences. Volume 77:Issue 3(2023)
• Page Start: 160
• Page End: 167
• Publication Date: 2022-12-21
• Subjects: adverse reactions -- conduct disorders -- disruptive -- dopamine agonists -- drug‐related side effects -- impulse control -- impulsive behavior -- psychopharmacology; Psychiatry -- Periodicals; Neurology -- Periodicals; 616.89
• DOI: 10.1111/pcn.13511
• Languages: English
• ISSNs: 1323-1316

Abstract

Abstract : Introduction: Impulse control disorders (e.g. pathological gambling, hypersexuality) may develop as adverse reactions to drugs. Pathogenetic hypotheses have mainly focused on D3‐receptor agonism, and switching to alternatives with different pharmacologic mechanisms represents a common management strategy. Nonetheless, treatment failure is common and gaining pathophysiological insights is needed. Aim: We aimed to identify targets potentially contributing to pathologic impulsivity. Method: We performed a pharmacovigilance‐pharmacodynamic study on dopamine agonists and antipsychotics using the Food and Drug Administration Adverse Event Reporting System (January 2004–December 2021). We estimated disproportionate reporting using the Bayesian information component. Using online public databases (IUPHAR, ChEMBL, PDSP, DrugBank), we calculated drug occupancies. To identify the targets potentially contributing to impulsivity, we fitted univariate regression models interpolating information components and occupancies within dopamine agonists and antipsychotics. Sensitivity analyses were performed to check for the robustness of the results. Results: Among 19 887 reports of impulsivity, 5898 recorded an antipsychotic, and 3100 a dopamine agonist. The more robust signals concerned aripiprazole (N = 3091; median information component [95% confidence interval] = 4.51[4.45–4.55]) and brexpiprazole (229; 4.00[3.78–4.16]) for antipsychotics, pergolide (105; 5.82[5.50–6.06]) and pramipexole (2009; 5.43[5.36–5.48]) for dopamine agonists. Robust, significant positive associations between drug occupancy and impulsivity reporting were found for D3 within dopamine agonists (beta = 1.52; P ‐value = 0.047) and 5‐HT1a within antipsychotics (1.92, 0.029). Conclusion: Our results supported the role of D3‐receptor agonism in inducing impulsivity in dopamine receptor agonists and identified a potential role of 5‐HT1a receptor agonism in antipsychotics. Investigating these receptors may drive towards a better management of drug‐induced impulsivity.